Figures 1: Comparison between the two groups of overall dialysis patients and non-dialysis patients by the boxplot
FIGURE 1
|
HD n=22 |
non |
p |
Age (Mean ±SD; y) |
70.1 ± 8.0 |
72.4 ± 8.5 |
0.305 |
Sex (M/F) |
14/8 |
23/13 |
0.985 |
DM |
9 (40.9%) |
13 (36.1%) |
0.784 |
HT |
18 (81.8%) |
24 (66.7%) |
0.243 |
HL |
9 (40.9%) |
13 (36.1%) |
0.784 |
Anticoagulant |
8 (36.4%) |
6 (16.7%) |
0.118 |
EF (Mean ±SD; %) |
70.5 ± 10.5 |
69.6 ± 7.6 |
0.344 |
BMI (Mean ±SD) |
21.6 ± 3.6 |
23.5 ± 4.3 |
0.124 |
Procedure of gastrectomy |
|
|
|
Distal gastrectomy |
13 (59.1%) |
21 (58.3%) |
0.955 |
Proximal gastrectomy |
0 (0%) |
3 (8.3%) |
0.164 |
Total gastrectomy |
9 (40.9%) |
12 (33.3%) |
0.585 |
Laparoscopy |
11 (50%) |
19 (52.8%) |
0.837 |
Operative time (Mean ±SD; minutes) |
232.5 ± 73.9 |
222.2 ± 59.6 |
0.779 |
Bleeding volume (Mean ±SD; mL) |
180.4 ± |
187.2 ± 208.4 |
0.671 |
Lymph node dissection |
|
|
|
D1 |
8 (36.4%) |
7 (19.4%) |
0.153 |
D1+ |
9 (40.9%) |
13 (36.1%) |
0.784 |
D2 |
5 (22.7%) |
16 (44.4%) |
0.159 |
Reconstruction |
|
|
|
B1 |
3 (13.6%) |
12 (33.3%) |
0.0965 |
B2 |
3 (13.6%) |
6 (16.7%) |
0.757 |
R-Y |
16 (72.7%) |
18 (50%) |
0.0882 |
Perioperative blood transfusion |
2 (9.1%) |
1 (2.8%) |
0.551 |
Invasion depth |
|
|
|
T1 |
14 (63.6%) |
16 (44.4%) |
0.156 |
T2 |
2 (9.1%) |
2 (5.6%) |
0.606 |
T3 |
1 (4.6%) |
6 (16.7%) |
0.169 |
T4 |
5 (22.7%) |
12 (33.3%) |
0.389 |
Lymph node metastasis |
6 (27.3%) |
14 (38.9%) |
0.367 |
v+ |
9 (40.9%) |
25 (69.4%) |
0.0323 |
ly+ |
13 (59.1%) |
25 (69.4%) |
0.421 |
CEA (Mean ±SD; U/mL) |
3.6 ± 1.6 |
2.9 ± 0.4 |
0.248 |
CA19-9 (Mean ±SD; U/mL) |
22.2 ± 25.1 |
31.8 ± 38.2 |
0.32 |
BNP (Mean ±SD; pg/mL) |
295.7 ± |
48.7 ± 56.9 |
< .0001 |
CRP (Mean ±SD; mg/dL) |
1.97 ± 2.83 |
0.40 ± 0.64 |
0.0074 |
ALB (Mean ±SD; g/dL) |
3.21 ± 0.74 |
3.58 ± 0.73 |
0.0662 |
WBC (Mean ±SD; /μL) |
6679 ± 2615 |
6791 ± 2454 |
0.522 |
PNI (Mean ±SD) |
38.3 ± 8.3 |
43.4 ± 7.8 |
0.046 |
NLR (Mean ±SD) |
4.16 ± 2.38 |
3.86 ± 3.18 |
0.259 |
PLR (Mean ±SD) |
196.5 ± |
192.1 ± 112.3 |
0.904 |
LMR (Mean ±SD) |
3.15 ± 1.12 |
4.60 ± 2.21 |
0.008 |
Postoperative |
3.2 ± 2.3 |
4.2 ± 8.7 |
0.297 |
Postoperative |
27.8 ± 24.1 |
24.7 ± 11.8 |
0.324 |
Postoperative complications (CD≧Ⅲ)) |
2 (9.1%) |
2 (5.6%) |
0.63 |
Postoperative complications (CD≧II)) |
5 (22.7%) |
8 (22.2%) |
0.964 |
Table 1: Overall comparison of dialysis and non-dialysis patient groups
HD: Hemodialysis; SD: Standard Deviation; y: Years; M: Male; F: Female; DM: Diabetes Mellitus; HT: Hypertension; HL: Hyperlipemia; EF: Ejection Fraction; BMI: Body Mass Index; B1: Billroth I; B2: Billroth II; R-Y, Roux-en-Y; VI: venous invasion; LY: Lymphatic Invasion; CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; BNP: brain natriuretic peptide; CRP: C-reactive protein; ALB: Albumin; WBC: white blood cell; PNI: prognostic nutritional index; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; LMR: lymphocyte to monocyte ratio; CD: Clavien–Dindo classification
|
HD n=11 |
non HD n=19 |
p |
Age (Mean ±SD; y) |
69.8 ± 7.5 |
71.9 ± 9.6 |
0.389 |
Sex (M/F) |
5/6 |
10/9 |
0.705 |
DM |
3 (27.3%) |
5 (26.3%) |
0.955 |
HT |
10 (90.9%) |
10 (52.6%) |
0.0321 |
HL |
4 (36.4%) |
6 (31.6%) |
0.789 |
Anticoagulant |
3 (27.3%) |
3 (15.8%) |
0.449 |
EF (Mean ±SD; %) |
73.7 ± 5.8 |
70.3 ± 5.8 |
0.155 |
BMI (Mean ±SD) |
20.2 ± 3.9 |
24.8 ± 4.6 |
0.015 |
Procedure of gastrectomy |
|
|
|
Distal gastrectomy |
5 (45.5%) |
13 (68.4%) |
0.216 |
Proximal gastrectomy |
0 (0%) |
3 (15.8%) |
0.165 |
Total gastrectomy |
6 (54.6%) |
3 (15.8%) |
0.0256 |
Operative time (Mean ±SD; minutes) |
258.6 ± 44.0 |
246.1 ± 50.8 |
0.636 |
Bleeding volume (Mean ±SD; mL) |
116.1 ± 154.2 |
99.6 ± 179.5 |
0.682 |
Lymph node dissection |
|
|
|
D1 |
4 (36.4%) |
4 (21.1%) |
0.361 |
D1+ |
5 (45.5%) |
10 (52.6%) |
0.705 |
D2 |
2 (18.2%) |
5 (26.3%) |
0.612 |
Reconstruction |
|
|
|
B1 |
1 (9.1%) |
11 (57.9%) |
0.0086 |
R-Y |
10 (90.9%) |
8 (42.1%) |
0.0086 |
Perioperative blood transfusion |
2 (18.2%) |
0 (0%) |
0.0544 |
Invasion depth |
|
|
|
T1 |
8 (72.7%) |
13 (68.4%) |
0.804 |
T2 |
1 (9.1%) |
1 (5.3%) |
0.686 |
T3 |
1 (9.1%) |
3 (15.8%) |
0.603 |
T4 |
1 (9.1%) |
2 (10.5%) |
0.9 |
Lymph node metastasis |
2 (18.2%) |
1 (5.3%) |
0.256 |
v+ |
3 (27.3%) |
10 (52.6%) |
0.177 |
ly+ |
6 (54.6%) |
9 (47.4%) |
0.705 |
CEA (Mean ±SD; U/mL) |
3.89 ± 2.03 |
2.49 ± 1.67 |
0.0407 |
CA19-9 (Mean ±SD; U/mL) |
20.7 ± 25.6 |
27.2 ± 36.3 |
0.505 |
BNP (Mean ±SD; pg/mL) |
345.1 ± 292.6 |
28.6 ± 18.0 |
0.0003 |
CRP (Mean ±SD; mg/dL) |
1.45 ± 1.90 |
0.16 ± 0.20 |
0.0116 |
ALB (Mean ±SD; g/dL) |
3.34 ± 0.62 |
3.97 ± 0.49 |
0.0096 |
WBC (Mean ±SD; /μL) |
6234 ± 2239 |
6544 ± 1789 |
0.491 |
PNI (Mean ±SD) |
40.4 ± 6.1 |
47.4 ± 6.7 |
0.0179 |
NLR (Mean ±SD) |
3.36 ± 2.16 |
3.86 ± 3.25 |
0.606 |
PLR (Mean ±SD) |
200.5 ± 127.4 |
190.6 ± 124.0 |
0.897 |
LMR (Mean ±SD) |
3.72 ± 1.14 |
4.82 ± 2.44 |
0.245 |
Postoperative |
3.8 ± 5.5 |
3.3 ± 8.9 |
0.691 |
Postoperative |
24.5 ± 21.4 |
22.4 ± 12.0 |
0.567 |
Postoperative complications (CD≧Ⅲ) |
2 (18.2%) |
0 (0%) |
0.0544 |
Postoperative complications (CD≧II) |
2 (18.2%) |
4 (21.1%) |
0.85 |
Table 2: Comparison of dialysis and non-dialysis patient groups limited to cases of laparoscopic surgery
HD, hemodialysis; SD, standard deviation; y, years; M, male; F, female; DM, diabetes mellitus; HT, hypertension; HL, hyperlipemia; EF, ejection fraction; BMI, body mass index; B1, Billroth I; R-Y, Roux-en-Y; v, venous invasion; ly, lymphatic invasion; CEA, carcinoembry- onic antigen; CA19-9, carbohydrate antigen 19-9; BNP, brain natriuretic peptide; CRP, C-reactive protein; ALB, albumin; WBC, white blood cell; PNI, prognostic nutritional index; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; CD, Clavien–Dindo classification
|
Complications (+) n=5 |
Complications (ｰ) n=17 |
p |
Dialysis history (Mean ±SD; days) |
1125.4 ± 1044.7 |
2543.5 ± 3247.7 |
0.433 |
Age (Mean ±SD; y) |
67.0 ± 9.7 |
71.0 ± 7.6 |
0.556 |
Sex (M/F) |
4/1 |
10/7 |
0.387 |
DM |
2 (40%) |
7 (41.2%) |
0.963 |
HT |
5 (100%) |
13 (76.5%) |
0.231 |
HL |
3 (60%) |
6 (35.3%) |
0.323 |
Anticoagulant |
1 (20%) |
7 (41.2%) |
0.387 |
EF (Mean ±SD; %) |
72.6 ± 4.8 |
69.8 ± 11.7 |
0.969 |
BMI (Mean ±SD) |
21.7 ± 5.1 |
21.6 ± 3.3 |
1 |
Procedure of gastrectomy |
|
|
|
Distal gastrectomy |
3 (60%) |
10 (58.8%) |
0.963 |
Proximal gastrectomy |
0 (0%) |
0 (0%) |
— |
Total gastrectomy |
2 (40%) |
7 (41.2%) |
0.963 |
Laparoscopy |
3 (60%) |
8 (47.1%) |
0.611 |
Operative time (Mean ±SD; minutes) |
265.8 ± 127.8 |
222.6 ± 51.4 |
0.389 |
Bleeding volume (Mean ±SD; mL) |
281.4 ± 390.6 |
150.6 ± 210.8 |
0.695 |
Lymph node dissection |
|
|
|
D1 |
1 (20%) |
7 (41.2%) |
0.387 |
D1+ |
1 (20%) |
8 (47.1%) |
0.279 |
D2 |
3 (60%) |
2 (11.8%) |
0.0237 |
Reconstruction |
|
|
|
B1 |
0 (0%) |
3 (17.7%) |
0.312 |
B2 |
1 (20%) |
2 (11.8%) |
0.637 |
R-Y |
4 (80%) |
12 (70.6%) |
0.678 |
Perioperative blood transfusion |
1 (20%) |
1 (5.9%) |
0.334 |
Invasion depth |
|
|
|
T1 |
2 (40%) |
12 (70.6%) |
0.211 |
T2 |
1 (20%) |
1 (5.9%) |
0.334 |
T3 |
0 (0%) |
1 (5.9%) |
0.579 |
T4 |
2 (40%) |
3 (17.7%) |
0.294 |
Lymph node metastasis |
2 (40%) |
4 (23.5%) |
0.467 |
v+ |
3 (60%) |
6 (35.3%) |
0.323 |
ly+ |
4 (80%) |
9 (52.9%) |
0.279 |
CEA (Mean ±SD; U/mL) |
2.82 ± 0.90 |
3.83 ± 1.74 |
0.308 |
CA19-9 (Mean ±SD; U/mL) |
16.2 ± 11.4 |
23.9 ± 27.9 |
0.814 |
BNP (Mean ±SD; pg/mL) |
374.0 ± 294.2 |
272.7 ± 299.5 |
0.21 |
CRP (Mean ±SD; mg/dL) |
5.58 ± 3.58 |
0.91 ± 1.44 |
0.0029 |
Cr (Mean ±SD; mg/dL) |
8.95 ± 3.32 |
6.88 ± 2.00 |
0.137 |
ALB (Mean ±SD; g/dL) |
2.86 ± 0.78 |
3.32 ± 0.73 |
0.272 |
WBC (Mean ±SD; /μL) |
6104 ± 1732 |
6848 ± 2845 |
0.695 |
PNI (Mean ±SD) |
35.2 ± 9.2 |
39.2 ± 8.1 |
0.389 |
NLR (Mean ±SD) |
4.25 ± 2.46 |
4.14 ± 2.43 |
0.876 |
PLR (Mean ±SD) |
157.7 ± 66.4 |
207.9 ± 116.2 |
0.481 |
LMR (Mean ±SD) |
3.23 ± 1.56 |
3.13 ± 1.02 |
0.814 |
Postoperative |
8.1 ± 6.8 |
4.2 ± 1.4 |
0.006 |
Postoperative |
32.9 ± 28.8 |
26.2 ± 23.0 |
0.31 |
Table 3: Comparison between group with Clavien–Dindo classification class 2 or higher and non-complication group limited to dialysis patients
SD, standard deviation; y, years; M, male; F, female; DM, diabetes mellitus; HT, hypertension; HL, hyperlipemia; EF, ejection fraction; BMI, body mass index; B1, Billroth I; B2, Billroth II; R-Y, Roux-en-Y; v, venous invasion; ly, lymphatic invasion; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; BNP, brain natriuretic peptide; CRP, C-reactive protein; Cr, creatinine; ALB, albumin; WBC, white blood cell; PNI, prognostic nutritional index; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; LMR, lym- phocyte to monocyte ratio
Figures 1: Comparison between the two groups of overall dialysis patients and non-dialysis patients by the boxplot
HD, hemodialysis; BNP, brain natriuretic peptide; CRP, C-reactive protein; Cr, creatinine; ALB, albumin
Figure 2: Comparison between the two groups of dialysis patients and non-dialysis patients limited to cases of laparoscopic surgery by the boxplot
BNP, brain natriuretic peptide; CRP, C-reactive protein; Cr, creatinine; ALB, albumin
Figure 3: Comparison between group with Clavien–Dindo classification class 2 or higher and non-complication group limited to dialysis patients by the boxplot
Figure 4: Pooled odds ratios of each risk factor to Clavien–Dindo classification ≥2
Figures at a glance